CN116059305A

CN116059305A - Pharmaceutical composition for treating hysteromyoma

Info

Publication number: CN116059305A
Application number: CN202310058602.1A
Authority: CN
Inventors: 闵理国; 闵程豪; 闵程澜; 施维
Original assignee: Individual
Current assignee: Individual
Priority date: 2023-01-16
Filing date: 2023-01-16
Publication date: 2023-05-05

Abstract

The invention relates to a pharmaceutical composition for treating hysteromyoma, which comprises the following components: rhizoma Sparganii, curcumae rhizoma, radix et rhizoma Rhei, eupolyphaga Seu Steleophaga, olibanum, myrrha, tabanus, and fructus crataegi. The medicine is prepared into any conventional oral preparation by adopting a preparation method of a traditional Chinese medicine preparation, for example, the raw material medicines can be prepared into paste, electuary, pill, decoction and the like for use, and the medicine has the effects of warming and activating meridian, eliminating symptoms and removing blood stasis, and promoting qi circulation and blood circulation after being taken, and has obvious curative effect on hysteromyoma treatment.

Description

Pharmaceutical composition for treating hysteromyoma

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a pharmaceutical composition for treating hysteromyoma, which is a medicine prepared from a plurality of Chinese herbal medicines and used for treating hysteromyoma.

Background

At present, along with the increase of life rhythm and the increase of working pressure, many women have the problem of hysteromyoma, but various medicines sold in the existing market cannot fundamentally treat the problem of hysteromyoma.

In the prior art, during the period of oral mifepristone, hysteromyoma can shrink, but once the medicine is stopped, the hysteromyoma can quickly recover to the original size.

The medicine is prepared into oral preparation including ointment, granule, pill, decoction, etc. after being mixed with various Chinese medicine materials, and has the functions of warming channel, dredging meridian, eliminating disease, eliminating blood stasis, promoting qi and blood circulation, and can reduce hysteromyoma obviously until eliminating completely, and no recurrence after stopping medicine.

Disclosure of Invention

The invention aims at solving the problems in the prior art and provides a pharmaceutical composition for treating hysteromyoma, which aims at solving the defects of the existing medicines.

The aim of the invention can be achieved by the following scheme:

the invention provides a pharmaceutical composition for treating hysteromyoma, which comprises the following raw material components in parts by weight:

the invention also provides application of the pharmaceutical composition in preparing an oral preparation for treating hysteromyoma, wherein the oral preparation comprises one of paste, electuary, pill and decoction. The medicine of the invention is prepared into any conventional oral preparation by adopting a preparation method of a traditional Chinese medicine preparation, and for example, the raw material medicines can be prepared into paste, electuary, pill, decoction and the like for use.

When the oral preparation is a paste, the oral preparation is preferably 15 parts of rhizoma sparganii, 15 parts of rhizoma curcumae, 10 parts of raw radix et rhizoma Rhei, 15 parts of ground beetle, 10 parts of prepared frankincense, 10 parts of prepared myrrh, 15 parts of Tabanus and 20 parts of raw hawthorn; when the oral preparation is granule, the weight parts are preferably 15 parts of rhizoma sparganii, 15 parts of rhizoma curcumae, 8 parts of raw radix et rhizoma Rhei, 15 parts of Eupolyphaga Seu Steleophaga, 8 parts of Olibanum, 8 parts of Myrrha, 15 parts of Tabanus and 20 parts of raw fructus crataegi; when the oral preparation is a pill, the weight parts are preferably 10 parts of rhizoma sparganii, 10 parts of rhizoma curcumae, 8 parts of raw radix et rhizoma Rhei, 10 parts of Eupolyphaga Seu Steleophaga, 8 parts of Olibanum, 8 parts of Myrrha, 10 parts of Tabanus and 15 parts of raw fructus crataegi; when the oral preparation is a decoction, the weight parts are preferably 13 parts of rhizoma sparganii, 13 parts of rhizoma curcumae, 9 parts of raw radix et rhizoma Rhei, 13 parts of Eupolyphaga Seu Steleophaga, 9 parts of Olibanum, 9 parts of Myrrha, 12 parts of Tabanus and 18 parts of raw fructus crataegi.

In the invention, the raw radix et rhizoma Rhei is matched with the raw hawthorn pulp, so that the effect of promoting digestion is stronger. The eupolyphaga sinensis and the Tabanus are matched with the hawthorn flesh, so that the effect of promoting blood circulation is stronger. The functions of removing blood stasis and dredging collaterals are stronger when the common burreed rhizome, the zedoary, the prepared frankincense and the prepared myrrh are matched with the raw hawthorn pulp. The raw hawthorn pulp has the effects of promoting blood circulation, removing blood stasis, reducing blood fat and the like, has the effect of promoting digestion, is used for treating diseases such as meat food stagnation and the like, has an odd effect for eliminating hysteromyoma, and can play a stronger role in eliminating hysteromyoma by being matched with other medicines for promoting blood circulation and removing collaterals. The effect of eliminating hysteromyoma is greatly reduced due to the lack of the medicine for producing hawthorn.

The prepared Olibanum and Myrrha contains vinegar. The vinegar has the effects of promoting blood circulation, removing blood stasis, promoting digestion and resolving food stagnation, so that the vinegar can be used for treating hysteromyoma, and most women with hysteromyoma have symptoms of liver depression, and the vinegar can play a role in softening liver.

The dosage of the raw rhubarb, the Tabanus and the Eupolyphaga sinensis in the invention is large, so that the effect of removing blood stasis under the body is stronger, hysteromyoma can be reduced, and if the dosage is reduced, the effect of removing blood stasis under the body is smaller.

The invention can ensure that the components of the rhubarb which are downwards passed are not destroyed after the rhubarb is downwards passed or the raw rhubarb is prepared into pills, can play the best curative effect, and the compatibility of raw hawthorn and hawthorn is decocted or prepared into pills, so that the functional components of the other seven medicines for removing blood stasis and eliminating hysteromyoma are enhanced.

The wine treatment of Eupolyphaga Seu Steleophaga and Tabanus can enhance the effect of eliminating hysteromyoma.

Eight medicines of rhizoma sparganii, rhizoma curcumae, radix et rhizoma Rhei, eupolyphaga Seu Steleophaga, olibanum, myrrha, tabanus and fructus crataegi can be matched to achieve the synergistic effects of activating qi-flowing, promoting blood circulation, removing blood stasis, promoting tissue regeneration, removing blood stasis, and eliminating hysteromyoma. Wherein, the compatibility of rhizoma sparganii, rhizoma zedoariae, ground beetle, prepared frankincense, prepared myrrh, tabanus and raw radix et rhizoma Rhei can enhance the effect of activating blood and removing blood stasis, but has small effect of eliminating hysteromyoma. The compatibility of the rhizoma sparganii, the rhizoma curcumae, the ground beetle, the prepared frankincense, the prepared myrrh, the Tabanus and the raw hawthorn flesh can enhance the blood lipid reducing effect, promote blood circulation and remove blood stasis, so that the effect of eliminating hysteromyoma is enhanced. Therefore, the eight medicaments in the invention are combined together to ensure that the effect of removing blood stasis and eliminating hysteromyoma is longer.

The hawthorn pulp used in the invention has the following pharmacological actions:

(1) The ethanol extract of hawthorn can slowly and permanently reduce blood pressure;

(2) The antibacterial effect, the in vitro experiment of the hawthorn decoction has obvious inhibition effect on various bacteria;

(3) The hawthorn fluid extract has the effects of reducing blood cholesterol for experimental cholesterol atherosclerosis rabbits, and the total flavone in the hawthorn has the effects of reducing blood pressure and strengthening heart for anesthetized animals, and can relax coronary blood vessels;

(4) By animal experiment principle, the haw has the functions of dilating blood vessel and contracting uterus, so as to achieve the purpose of eliminating hysteromyoma. In addition, hysteromyoma of patients with hysteromyoma is easy to occur and increase, and experimental research on hawthorn has antibacterial effect and is helpful for hysteromyoma;

(5) Experiments prove that hawthorn has the effect of reducing cholesterol, and the higher the cholesterol is, the more qi and blood circulation of a human body are easy to be blocked, and hysteromyoma is easy to occur and increase.

Compared with the prior art, the invention has the following beneficial effects:

(1) The medicine composition has the effects of warming and activating meridian, eliminating symptoms and removing blood stasis, and promoting qi and blood circulation, and has obvious curative effect on hysteromyoma treatment;

(2) The invention has the function of reducing blood fat, and has obvious curative effect on high blood fat, fatty liver and the like;

(3) The invention has obvious thrombus eliminating effect, and can obviously improve systemic capillary circulation and palace artery blood flow variable flow rate. In addition, the medicine can eliminate thrombus and has obvious curative effect on coronary heart disease and cerebral infarction;

(4) The medicine has strong effects of promoting qi and blood circulation and removing blood stasis, and can also be used for treating diseases such as pulmonary nodules, thyroid nodules, breast nodules and the like;

(5) The medicine composition has the functions of warming and activating meridian, eliminating symptoms and blood stasis, promoting qi and activating blood circulation, and has obvious curative effect on ovarian cyst, varicose vein of lower limb and the like.

Detailed Description

The invention is further illustrated below in conjunction with specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The beneficial effects of the present invention are further illustrated by clinical trial statistics and typical cases.

Example 1

The embodiment provides a pharmaceutical composition for treating hysteromyoma, which is prepared by weighing 15g of rhizoma sparganii, 15g of rhizoma curcumae, 10g of raw radix et rhizoma Rhei, 15g of ground beetle, 10g of prepared frankincense, 10g of prepared myrrh, 10g of Tabanus and 20g of raw hawthorn.

Example 2

The embodiment provides a pharmaceutical composition for treating hysteromyoma, which is prepared by weighing 10g of rhizoma sparganii, 10g of rhizoma curcumae, 10g of raw radix et rhizoma Rhei, 15g of ground beetle, 10g of prepared frankincense, 10g of prepared myrrh, 15g of Tabanus and 20g of raw hawthorn.

Example 3

The embodiment provides a pharmaceutical composition for treating hysteromyoma, which is prepared by weighing 15g of rhizoma sparganii, 15g of rhizoma curcumae, 8g of raw radix et rhizoma Rhei, 10g of ground beetle, 8g of prepared frankincense, 9g of prepared myrrh, 15g of Tabanus and 20g of raw hawthorn.

Example 4

The embodiment provides a pharmaceutical composition for treating hysteromyoma, which is prepared by weighing 15g of rhizoma sparganii, 15g of rhizoma curcumae, 10g of raw radix et rhizoma Rhei, 10g of ground beetle, 10g of prepared frankincense, 10g of prepared myrrh, 15g of Tabanus and 15g of raw hawthorn pulp.

The embodiments 1-4 of the invention are used for the treatment of patients, and all achieve good treatment effects. Wherein, the decoction of the example 1 is used for patients with hysteromyoma, and the specific treatment process is as follows.

Patient one,

Name: number x, gender: female, age: 29, occupation: nurse, address: pudong New district, date: 2016-12-22.

History of menstruation: the 14 years old, 7/30-32 days period, medium volume, dark color before red color, and blood clot. The breast pain before menstruation is 3-5 days, and the breast pain is slightly soreness of waist and distending pain of lower abdomen. The latest menstruation was on 11 months, 11 days, 12 months and 14 days.

Marital history: wedding is carried out in 2016 month 5, sexual life is normal, and semen is recovered after the same house.

Other cases: the people feel cold in winter, and the red eruption points of the face are more sent out.

History of fertility: left-hand ectopic pregnancy resection in 2012 and contraception to date.

History of past illness: laparoscopically descending right uterine platysma removal and right tubal fasciae cyst dissection in 2011. (2016-11-19) Yang Sai Hospital yin-excess: uterus: 45X43X30mm, uterine fibroid: 11X10X10mm, pelvic effusion: (2016-11-19) 12 high-risk HPVs: positive, multiple thyroid nodules. (2016-11-22) Red house HSG, right transfusion is not smooth and the umbrella end is possibly stuck.

Usual symptoms: sleep and normal diet.

Leucorrhea condition: normal.

Outpatient inspection: a thin pulse, a thin tongue coating and a red tongue.

Lower abdomen middle pressure pain (-) lower abdomen two sides pressure pain left (+), right (+), two sides pressure pain left (-) of umbilicus, right (+).

Diagnosis of traditional Chinese medicine: 1. poor ovarian function; 2. right transfusion is very unsmooth; 3. pelvic cavity adhesion effusion; 4. uterine fibroids.

Treatment rules: warming and activating meridian, eliminating symptoms, removing blood stasis, promoting qi and activating blood circulation.

The prescription comprises the following components: 15g of rhizoma sparganii, 15g of rhizoma curcumae, 10g of raw radix et rhizoma Rhei, 15g of ground beetle, 10g of prepared frankincense, 10g of prepared myrrh, 10g of Tabanus and 20g of raw hawthorn.

After the upper treatment, the ultrasonic B is performed on the following days of 2017, 6 and 11: uterine fibroids have been absent.

Patient II,

Name: shux, sex: female, age: 35, occupation: staff, address: pudong New district, date: 2020-6-5.

Menstrual cycle is 3-5/20-30 days, 7 days for 4 months, 25 days after menstruation, and the menstruation is not clean. Sleep and urinate normally. The feces are dry and hard for 1 time in 2-3 days. Red house hospital B-ultrasound at 6 months and 2 days 2020: uterus size is 99×110×102mm, and hysteromyoma is 47×46×43mm. 4/8/2020, CA125:122.6 thin and yellow coating and normal tongue. The syndrome differentiation of traditional Chinese medicine: stasis blocks uterus, liver-hyperactivity and spleen-deficiency. Treatment rules: liver soothing, spleen strengthening, and symptoms eliminating and blood stasis removing effects.

The prescription comprises the following components: 15g of rhizoma sparganii, 15g of rhizoma curcumae, 10g of raw radix et rhizoma Rhei, 15g of ground beetle, 10g of prepared frankincense, 10g of prepared myrrh, 10g of Tabanus and 20g of raw hawthorn flesh

After the upper treatment, the ultrasonic B is performed on 7 months and 8 days in 2020: uterus size is 80×94×96mm, uterus myoma 36×40×33mm. CA125:58.8. after the medicine is continuously taken, the medicine is taken in 2021, 3 months and 10 days B ultrasonic therapy: the uterus is normal in size and has no hysteromyoma.

Patient III,

Name: che x, sex: female, age: 44, occupation: staff, address: qingdao district, date: 2017-9-2.

Ultrasound at 2017, 4 months and 27 days: uterus 73×57×68mm, endometrium 20mm, uterine fibroid 28×35×32mm, left ovarian cyst: 17X 14X 16mm. Menstrual cycle 7/30-60+ days, moderate amount, red color, blood clot, menstruation for 6 months 20 days, 7 months 20 days, 8 months 25 days, premenstrual breast distention for 2 days, and lower abdominal pain for 2 days. Sleep, normal urination, 1 time in 2 days, and dryness. The leucorrhea is normal. A deep and thready pulse with thin and white coating and a normal tongue. The syndrome differentiation of traditional Chinese medicine: the blood stasis blocks the uterus. Treatment rules: has the main effects of eliminating symptoms, removing blood stasis, promoting blood circulation and removing obstruction in collaterals.

After the upper treatment, the ultrasonic B is performed on the following days of 2017, 9 and 15: endometrium is already normal. Ultrasound at 2017, 11, 25: uterus 62×54×58mm, endometrium 6mm, uterus myoma 20×15×12mm. Ultrasound B was continued for 28 days 3 months 2018: the uterus is normal in size and has no hysteromyoma.

Further, 100 cases of hysteromyoma patients with deficiency-cold uterus and stasis uterus are observed by taking the decoction in example 1, 75 patients with obvious effects take the decoction for three months, 17 patients take the decoction, 8 patients with obvious effects are temporarily absent, and the total effective rate is 92%.

Comparative example 1

This comparative example provides a pharmaceutical composition for the treatment of uterine fibroids, which has substantially the same composition as in example 1, except that: no fructus crataegi is added.

100 clinical hysteromyoma patients have 63 patients with obvious effects in three months, 9 patients are improved, 28 patients with obvious effects are temporarily absent, and the total effective rate is 72%.

Comparative example 2

This comparative example provides a pharmaceutical composition for the treatment of uterine fibroids, which has substantially the same composition as in example 1, except that: raw radix et rhizoma Rhei is not added.

100 clinical hysteromyoma patients have 65 patients with obvious effects in three months, 10 patients are improved, 25 patients with obvious effects are absent, and the total effective rate is 75%.

Comparative example 3

This comparative example provides a pharmaceutical composition for the treatment of uterine fibroids, which has substantially the same composition as in example 1, except that: the fructus crataegi is replaced by Raphani semen.

Comparative example 4

This comparative example provides a pharmaceutical composition for the treatment of uterine fibroids, which has substantially the same composition as in example 1, except that: the dosage of part of the components is less, the raw radix et rhizoma Rhei is 5g, the ground beetle is 5g, and the Tabanus is 5g.

100 clinical hysteromyoma patients have obvious effects of 60 patients in three months, 8 patients are improved, 32 patients with obvious effects are absent temporarily, and the total effective rate is 68%.

Comparative example 5

This comparative example provides a pharmaceutical composition for the treatment of uterine fibroids, which has substantially the same composition as in example 1, except that: the raw hawthorn pulp is not added and the raw radix et rhizoma Rhei is 30g.

100 clinical hysteromyoma patients have 65 patients with obvious effects in three months, 12 patients with obvious effects in three months, 23 patients with obvious effects in the past, and the total effective rate is 77%.

Comparative example 6

This comparative example provides a pharmaceutical composition for the treatment of uterine fibroids, which has substantially the same composition as in example 1, except that: 30g of raw hawthorn and dried meat are not added.

100 clinical hysteromyoma patients have 68 people with obvious effects in three months, 13 people are improved, 19 people with obvious effects are absent, and the total effective rate is 81%.

Example 5

The embodiment provides a pharmaceutical composition for treating hysteromyoma, which comprises the following two parts:

a: 5 parts of rhizoma sparganii; 5 parts of curcuma zedoary; 5 parts of ground beetles; 4 parts of prepared frankincense; 4 parts of myrrh; 5 parts of Tabanus; 15 parts of raw hawthorn.

B: 5 parts of rhizoma sparganii; 5 parts of curcuma zedoary; 5 parts of ground beetles; 4 parts of prepared frankincense; 4 parts of myrrh; 5 parts of Tabanus; 8 parts of raw radix et rhizoma Rhei.

The prescription consisting of A and B is used for 100 cases of clinical hysteromyoma patients, 75 patients with obvious effects are obtained in three months, 17 patients are improved, 8 patients with obvious effects are not obtained, and the total effective rate is 92 percent

The prescription composed of two A parts is used for 100 cases of clinical hysteromyoma patients, 65 patients with obvious effect take place in three months, 10 patients are improved, 25 patients with obvious effect take place temporarily, and the total effective rate is 75 percent

The prescription composed of two parts of B is used for 100 cases of clinical hysteromyoma patients, 63 patients with obvious effect take place in three months, 9 patients are improved, 28 patients with obvious effect take place temporarily, and the total effective rate is 72 percent

According to clinical observation, the combination of A and B can play a role in synergy.

In addition, according to clinical observation, the composition of the medicine has the effects of activating blood, dredging collaterals and reducing blood fat after the treatment of examples 1, 2, 3 and 4. So that the blood fat of the patients with high blood fat is obviously reduced, and the traditional Chinese medicine composition has obvious treatment effects on coronary heart disease, cerebral infarction, pulmonary nodule, thyroid nodule, breast nodule, ovarian cyst, varicose vein of lower limbs and the like.

The foregoing describes specific embodiments of the present invention. It is to be understood that the invention is not limited to the particular embodiments described above, and that various changes and modifications may be made by one skilled in the art within the scope of the claims without affecting the spirit of the invention.

Claims

1. The pharmaceutical composition for treating hysteromyoma is characterized by comprising the following raw material components in percentage by weight:

2. use of the pharmaceutical composition of claim 1 for the preparation of an oral formulation for the treatment of uterine fibroids.

3. The use according to claim 2, wherein the oral formulation comprises one of a paste, a granule, a pill, a decoction.

4. The use according to claim 3, wherein when the oral preparation is a paste, the pharmaceutical composition comprises 15 parts by weight of rhizoma sparganii, 15 parts by weight of rhizoma zedoariae, 10 parts by weight of raw radix et rhizoma Rhei, 15 parts by weight of Eupolyphaga Seu Steleophaga, 10 parts by weight of Olibanum, 10 parts by weight of Myrrha, 15 parts by weight of Tabanus and 20 parts by weight of raw hawthorn.

5. The use according to claim 3, wherein the oral preparation is granule, the pharmaceutical composition comprises 15 parts by weight of rhizoma sparganii, 15 parts by weight of rhizoma zedoariae, 8 parts by weight of raw radix et rhizoma Rhei, 15 parts by weight of Eupolyphaga Seu Steleophaga, 8 parts by weight of Olibanum, 8 parts by weight of Myrrha, 15 parts by weight of Tabanus, and 20 parts by weight of raw fructus crataegi.

6. The use according to claim 3, wherein the oral preparation is a pill, the pharmaceutical composition comprises 10 parts by weight of rhizoma sparganii, 10 parts by weight of rhizoma zedoariae, 8 parts by weight of raw radix et rhizoma Rhei, 10 parts by weight of Eupolyphaga Seu Steleophaga, 8 parts by weight of Olibanum, 8 parts by weight of Myrrha, 10 parts by weight of Tabanus, and 15 parts by weight of raw fructus crataegi.

7. The use according to claim 3, wherein when the oral preparation is a decoction, the pharmaceutical composition comprises 13 parts by weight of rhizoma sparganii, 13 parts by weight of rhizoma zedoariae, 9 parts by weight of raw radix et rhizoma Rhei, 13 parts by weight of Eupolyphaga Seu Steleophaga, 9 parts by weight of Olibanum, 9 parts by weight of Myrrha, 12 parts by weight of Tabanus and 18 parts by weight of raw hawthorn.